RGC SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Deadline on June 23, 2026

Why It Matters

The deadline determines who can steer the litigation and potentially capture a larger share of any recovery, directly affecting investors’ ability to recoup losses from Regencell’s sharp price decline.

Key Takeaways

• Regencell shares fell 18.56% after DOJ investigation disclosure
• Class‑action deadline is June 23 2026 for lead plaintiff election
• Investors who bought between Oct 28 2024‑Oct 31 2025 may qualify
• Potential recovery could offset losses from $13.56 share price
• Faruqi & Faruqi urges whistleblowers and shareholders to contact them

Pulse Analysis

The filing of a federal securities class action against Regencell Bioscience Holdings (NASDAQ:RGC) has entered a critical phase. The court‑appointed lead plaintiff—who must hold the largest financial stake and be typical of the class—guides strategy and settlement negotiations. Faruqi & Faruqi, a national securities litigation firm, reminds potential plaintiffs that the deadline to petition the court for lead‑plaintiff status is June 23 2026. Investors who purchased RGC shares between October 28 2024 and October 31 2025 are eligible to file, and their participation can influence the size and timing of any recovery.

Regencell’s troubles intensified after an October 31 2025 SEC filing revealed a Department of Justice subpoena probing trading irregularities and broader corporate matters. The disclosure triggered an 18.56% plunge, sending the ordinary share price to $13.56, a $3.09 drop per share. Management warned of mounting legal costs and the possibility of fines, penalties, or settlements that could exceed any insurance coverage. Such exposure not only threatens immediate shareholder value but also raises questions about the company’s governance, compliance controls, and future financing prospects.

For investors, the reminder from Faruqi & Faruqi underscores the importance of timely legal counsel when securities appear misrepresented. Acting before the June 23 2026 cut‑off can secure a seat as lead plaintiff, potentially increasing a claimant’s share of any settlement. The firm also solicits information from whistleblowers, former employees, and other insiders, a tactic that can strengthen the class’s case and accelerate resolution. As the biotech sector faces heightened regulatory scrutiny, similar class actions may become more common, prompting shareholders to monitor disclosures closely and consider litigation as a risk‑mitigation tool.